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Purpose  
Amplification of the epidermal growth factor receptor (EGFR) gene is a common 
oncogenic alteration in glioblastoma making it a prime target for therapy. However, small 
molecule inhibitors of the EGFR tyrosine kinase failed in clinical trials for glioblastoma. 
Here we aimed at investigating the molecular effects of preoperative treatment with the 
tyrosine kinase inhibitor gefitinib on the EGFR signalling pathway in glioblastoma tissue.  
Patients and Methods 
In a phase II trial, 22 patients selected for re-operation of recurrent glioblastoma were 
treated at least 5 days with 500 mg gefitinib prior to surgery, followed by post-operative 
gefitinib until recurrence. Resected glioblastoma tissues were tested for drug 
concentrations and EGFR-pathway activity using phosphorylation specific assays. 
Results 
Glioblastoma tissues exhibited high concentrations of gefitinib (median, 4,100 ng/g). The 
EGFR was efficiently dephosphorylated in treated patients as compared to a control 
cohort of 12 patients. However, downstream pathway constituents did not seem to be 
affected. In contrast, in vitro treatment of a glioblastoma cell line, BS-153, with 
endogenous EGFRwt amplification and EGFRvIII expression resulted not only in 
dephosphorylation of the EGFR, but also of key regulators in the pathway like AKT. A 
respective in vivo model, treating established xenografts similar to the human 
glioblastoma, showed dephosphorylation of the EGFR, without affecting downstream 
signal transductors.  
Conclusion 
Gefitinib reaches high concentrations in the tumor tissue and efficiently 
dephosphorylates its target. However, regulation of downstream signal transducers in 
the EGFR pathway seems to be dominated by regulatory circuits independent of EGFR 
phosphorylation. 
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INTRODUCTION 
The epidermal growth factor receptor (EGFR) offers a particularly attractive target in 
glioblastoma therapy, since it is overexpressed in 60% of glioblastoma usually 
associated with high level amplification of the EGFR gene. Small molecule drugs have 
been developed to specifically target the catalytic kinase domain of the EGFR to prevent 
downstream signaling 1. In NSCLC particularly good response was associated with 
mutations in the EGFR located around the ATP-binding pocket 2,3. In glioblastoma, 
however, such mutations have not been found 4. Some missense mutations have been 
identified in the extracellular domain of a fraction of cases (14%) with potentially 
activating properties 5, and were usually associated with amplification of the locus. The 
most common alteration (20%), is the truncation mutant lacking exons 2 to 7 (EGFRvIII) 
affecting the extra cellular domain involved in dimerization and ligand binding that has 
been associated with constitutive phosphorylation of the receptor conferring an 
oncogenic potential 6,7.  
 A first publication 8 on a phase II trial testing the EGFR-inhibitor gefitinib in 
recurrent glioblastoma reported that response to treatment was not correlated with 
expression of the EGFR, although the authors have not excluded insufficient drug 
penetration of the tumor. As in most clinical trials for glioblastoma, enzyme inducing 
antiepileptic drugs (EIAEDs) were allowed in this study that have been shown to reduce 
systemic availability of the small molecule inhibitors of the EGFR 9. In the meantime 
further phase II trials have been reported testing erlotinib or gefitinb in recurrent or 
progressive glioblastoma, summarized in Yung et al. 10, or in newly diagnosed 
glioblastoma as addition to combined chemo-radiotherapy with temozolomide 11, overall 
with disappointing efficacy.  
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 The occasional responses observed in these trials incited several studies to 
search for predictive molecular markers in the diagnostic tissue of the initial surgery that 
would allow future patient selection (reviewed in Brandes et al. 12). Several sets of 
markers with predictive value for response to therapy were proposed, comprising 
expression of EGFR, amplification of the EGFR gene, lack of elevated levels of AKT 
phosphorylation, and absence of EGFRvIII expression 13, while another study suggested 
better response of tumors with expression of EGFRvIII and expression of PTEN 14. The 
markers proposed in these small studies could not be confirmed in subsequent trials, 
including a randomized phase II trial 9, although low p-AKT showed a trend for 
association with better outcome. The difficulty to successfully target one of the most 
common activated oncogenic pathways operative in glioblastoma has drastically 
revealed the complexity of the regulation of receptor tyrosine kinase (RTK) signaling that 
requires further investigations.  
 Here we present a phase II clinical trial designed to elucidate potential reasons for 
the unexpected low response rates of glioblastoma to EGFR inhibitors in previous 
clinical studies, by addressing the following questions: (i) does the drug reach the tumor 
across the blood-tumor barrier, (ii) is the EGFR dephosphorylated by the drug, and (iii) 
what are the effects on downstream signaling. To this end, patients selected for surgery 
for recurrent glioblastoma were offered participation in a trial with the EGFR inhibitor 
gefitinib, comprising 5 day pre-operative treatment, followed by postoperative treatment 
until recurrence or undue side effect. The translational research design included 
molecular profiling of the human glioblastoma samples obtained from the patients 
enrolled, and a control set. These efforts were complemented by an experimental in vitro 
and in vivo model using a tumorigenic glioblastoma cell line with an endogenous EGFR 
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amplification and expression of EGFRvIII to aid interpretation of the “noisy” data 
obtained from human tumors, where no before and after therapy sampling is possible.  
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PATIENTS AND METHODS 
 
Patients selected for re-operation of a recurrent glioblastoma at the University Hospital 
in Zurich and Bern, Switzerland, were offered to participate in a phase II open label 
study of pre- and postoperative use of ZD1839 (gefitinib) including translational research 
(www.clinicaltrials.gov, NCT00250887). Patients were treated at least 5 days with 500 
mg gefitinib prior to surgery, followed by post-operative daily use, continuously until 
tumor progression or occurrence of intolerable side effects. Patients on cytochrome 
P450 isoenzyme CYP3A4-inducing antiepileptic drugs (EIAEDs) were changed to a 
nonenzyme-inducing drug, because of predicted ensuing interactions of EIAEDs with 
gefitinib metabolism, reducing its systemic availability. The trial was approved by the 
local ethic committees. Resected tumor tissues and plasma samples were snap frozen 
for further analysis. The following eligibility criteria applied: 18 years and older, fresh 
frozen sample obtainable, informed consent for translational research; exclusion criteria 
comprised enzyme inducing antiepileptic drugs. Archived fresh frozen samples of 
recurrent glioblastoma were used as controls. Patient criteria are summarized in Table 
1. All tumor samples underwent central pathology. Frozen tumor tissue was evaluated 
for tumor content on a Hematoxilin & Eosin stained frozen section. Samples with a tumor 
content below 50% were excluded for molecular analysis. 
 
Drug concentrations 
Frozen tumor tissue and plasma samples were sent to the Laboratory Analytico Medinet 
B.V. (Breda, NL) to quantify the concentration of gefitinib by high performance liquid 
chromatography coupled to tandem mass spectrometry as described previously 15 ,16. 
The gefitinib concentrations in the BS-153 xenografts and the mouse plasma were 
determined at the quantitative Mass Spectrometry Facility (qMSF) at the Lausanne 
University Hospital using the same technology with minor modifications. The tumor 
tissue homogenates were prepared at 200 mg of wet weight/ml in phosphate buffer 
using a Fast Prep homogenizer (MP biomedicals, Basel, Switzerland). 
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Cell line and xenograft model 
The human glioblastoma cell line BS-153 that comprises an amplified EGFR and 
expresses the mutant EGFRvIII 17, was cultured in low serum (0.5% FCS) and treated 
with 1, 5 and 10 M gefitinib (ZD 1839, AstraZeneca) for 24 h. For in vivo experiments, 
107 cells were injected subcutaneously into the flanks of immune compromised mice 
(Swiss nu/nu; Iffa Credo; RCC, BRL). When the tumors reached 1 cm in diameter the 
mice were randomized and treated (p.o.) or not with a daily dose of 7 mg/kg/day gefitinib 
(suspended in 1% w/v Tween 80) by gavage for 5 days that is equivalent to the human 
dosing scheme of 500 mg/day (70 kg). Tumor tissues were harvested 4 h after the last 
dose and snap frozen or embedded in paraffin for further analysis. The experiments 
were approved by the local authorities (protocol VD_1181.3). 
 
Tissue Micro Array, Fluorescence In Situ Hybridization (FISH) and 
Immunohistochemistry (IHC) 
A tissue micro array (TMA) was constructed from paraffin embedded tumor blocks 
available from patients and the xenografts in nude mice derived from the human cell line 
BS-153. FISH for determination of EGFR copy number was performed and scored as 
described previously 9. The EGFR copy number was normalized by a centromeric probe 
on chromosome 12 (CEP12). Immunohistochemical investigations were carried out 
according to standard procedures for paraffin sections using a heat induced epitope 
retrieval technique (HIER) in citrate buffer (pH 6.0; pressure cooker, 3–5 min) and 
overnight incubation with the primary antibody. The following antibodies were used, p-
mTOR (1:50, CellSignaling), PTEN (1:50, CellSignaling), CycD (1:50, Upstate). The 
immunostaining was scored semi-quantitatively (scores, 0–3). 
 
Real-Time Quantitative polymerase chain reaction (qPCR)  
DNA and RNA were isolated from frozen tissue using the Qiagen AllPrep DNA/RNA Kit 
(Qiagen, 80204). DNA from paraffin sections was isolated as described before 18. The 
EGFR gene copy number was determined on DNA isolated from macro-dissected 
paraffin embedded glioblastoma tissue by the relative qPCR comparative Ct (2-delta delta 
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Ct) method using DNM1L (12p11.21) as reference gene (primer sets: EGFR-F_669 
ATGTCCGGGAACACAAAGAC, EGFR-R_670 TTATCTCCCCTCCCCGTATC, amplicon 
size 104 bp; DNM1L-F_671 TCAGATGTTAAAGCTGCCATTT, DNM1L-R_672 
TCCCGAGCAGATAGTTTTCG, amplicon size 101 bp). Q-PCR was performed on a 
Rotor Gene 6000 Real-Time PCR system (Corbett Life Science) using the Fast SybR 
Green Master Mix (Applied Biosystem). DNA from peripheral blood lymphocytes served 
as normal reference, and cell line BS-153 as positive control for high level amplification. 
Quantitative reverse transcription PCR (qRT-PCR) was employed for expression 
analysis of EGFRwt and EGFRvIII at the Genetics Platform at the University of Geneva 
as described previously 19. 
 
Western blot and Bio-Plex analysis  
Protein from snap frozen human glioblastoma, xenografts, and cell lines were extracted 
with the Bio-Plex cell lysis kit (Bio-Rad # 171-304011) according to manufacturer’s 
protocol. The protein concentration was determined (BCA, Pierce #23250). Western blot 
analysis was performed with 20 mg of protein using 7.5% and 10% SDS-PAGE gels, 
and subsequent transfer to a nitrocellulose membrane (Hybond-C, Amersham Life 
Science). The phosphorylation status of the following proteins was evaluated using 
antibodies from Cell Signaling: p-EGFR (#4404), p-AKT (#9271), p-mTOR (#2971) p-
elf4G (#2441), and p-p90RSK (#9341) that were revealed by luminescence (BM 
Chemiluminescence Blotting Substrate, Roche, #1500694) on films or on a 
bioluminescence image reader (LAS-4000, Fuji). Tot-Erk1/2 (#9102) and tubulin (Sigma 
# T5168) served as loading controls.  
The Multiplexing Bio-Plex total target and phosphoprotein assay (Bio-Rad) was 
performed at the platform of the Center of Integrated Genomics (CIG) at the University 
of Lausanne according to Bio-Plex Phosphoprotein detection instruction manual with 
0.5mg/ml protein in 96 wells (duplicate). The following phospho-proteins were 
measuerd: pEGFR (pan-phospho), p-AKT (Ser473), p-GSK-3α/β (Ser21/Ser9), p-NFB 
p65 (Ser536), p-STAT3 (Tyr705), p-ERK1/2 (Thr202/Tyr204,Thr185/Tyr187), p-
MEK1(Ser217/Ser221), p-p38MAPK(Thr180/Tyr182), p-p90RSK (Thr359/Ser363), p-p70S6 
Kinase (Thr421/Ser424), p-S6 ribosomal Protein (Ser235/Ser236), p-PDGFR-B (Tyr751) and 
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p-SRC (Tyr416). The following total proteins were determined, tot-ERK1/2 (#171-
V32238), tot-p38MAPK (#171-V31336), tot-EGFR, tot-MEK1, and tot-AKT. Tot-ERK1/2 
was present on all plates and was used for normalization of the data-set after log2-
transformation.  
 
Statistical Methods 
Statistical significance of differences between treatments was evaluated with a non-
parametric test, Wilcoxon's test and the difference between subgroups was tested by 
Kruskal & Wallis' test. The independence between the two variables was tested by exact 
Fisher's test. A Monte-Carlo test on between-group inertia (global test) was performed to 
test the overall difference between treated and untreated patients 20. The heatmap 
representations were obtained with the Ward's algorithm using euclidean distance. The 
data was scaled and centered by phospho-proteins if not stated differently. All analyses 
and graphical representation were done in R 21 (URL http://www.R-project.org ) and the 
R packages gplots and ade4 22. 
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RESULTS 
 
 Twenty-two patients with recurrent glioblastoma selected for second surgery were 
enrolled between May 2005 and July 2007. Patients were treated for a median of 7.5 
days (range 5 to 150 days) with 500 mg gefitinib daily prior to surgery, followed by post-
operative gefitinib until recurrence. The study outline is depicted in Fig. S1. Central 
review confirmed recurrent glioblastoma in all cases. For three cases no frozen tissue 
became available, and several cases had to be excluded for molecular analysis, 
because the available frozen tissue consisted of >80% necroses or showed only 
reactive changes. Samples considered for further analysis had to display >50% compact 
viable tumor tissue (Table 1). 
 
EGFR amplification status 
 EGFR amplification was identified in 7 of 22 (32%) patients in the gefitinib group 
and 7 of 12 (58%) patient samples of the control group, as determined by FISH on the 
TMA and/or by qPCR from whole tumor sections (Table 1, Fig.1). A good correlation of 
the copy number was observed between both technologies (rpearson=0.87 and 
rspearman=0.83). For three patients we had to infer the EGFR status from the analysis of 
the glioblastoma tissue from the first resection, as the tissues obtained at re-operation 
did not comprise enough tumor cells. Overexpression of the wild-type EGFR was 
associated with amplification of the EGFR gene, but no linear correlation was observed. 
Expression of the EGFRvIII was detectabled in two glioblastoma with an amplified EGFR 
status. (Fig. 1) 
 
Gefitinib concentrations in tumor tissue and plasma 
The median concentration of gefitinib in the tumor tissue was 4,100 ng/g (range 
16 to 26,000 ng/g), while the respective median concentration in the plasma was more 
than 20x lower 181 ng/ml (4 to 483 ng/ml) (p<0.0001). The median time laps between 
the last drug dose and collection of the tumor tissue and the blood sample was 5 h and 5 
h 30 min, respectively. One patient did not take the drug on the day of surgery, reflected 
in very low drug concentrations in the tumor and the blood, respectively (Fig. 2). Timed 
information was only recorded in one center, however, drug concentrations suggested a 
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similar timeframe for tissue and blood collection for the other patients. The mean 
gefitinib concentration in the mouse BS-153 xenografts (n=9) was 1,669 ng/g (range, 
457 to 3,620 ng/g) and 226 ng/ml (range, 65-336 ng/ml) in the serum (n=4). The tumors 
were harvested 4h after the last gavage of drug.  
 
Patient outcome 
 The median survival after initiation of gefitinib treatment was 8.8 months. No 
difference was observed between patients with an amplified or a normal EGFR status. 
However, patients whose resected tissue had to be excluded for molecular analysis due 
to predominantly necrotic tissue had longer survival (logrank, P=0.004). This may be an 
indication of pseudo-progression. However, the small patient numbers preclude proper 
analysis and interpretation of this observation.   
 
Molecular analysis of the EGFR signalling pathway in glioblastoma 
In order to investigate the effect of gefitinib on activation of the EGFR and 
respective downstream signaling, a phosphorylation screen for a selected panel of 12 
published EGFR pathway signal transductors was performed. Beside pEGFR, it included 
constituents such as pAKT, pERK1/2 or pS6RP to cover distinct aspects of the pathway. 
Further, it included PDGFR-B and SRC two important players in glioblastoma. PDGFR-B 
activates elements of the same pathway, while SRC has to been reported to be an 
effector of EGFR signaling 23. Comparison between treated and untreated patients 
revealed that there was a border line significant decrease of phosphorylation of the 
EGFR (p=0.053), and surprisingly an increase of p-ERK1/2 phosphorylation (p=0.076). 
The phosphorylation of the other signaling transductors were not significantly changed. 
When stratifying for the EGFR amplification status, there was a significant reduction of 
EGFR phosphorylation (p=0.006), indicating efficient dephosphorylation by gefitinib as 
indicated by box plots in Figure 3A. Further, a trend for increased phosphorylation of 
ERK1/2 (p=0.104) was observed (Fig. 3B). The statistical analysis for all phospho-
proteins is summarized in Table S1 and the respective box plots are displayed in Fig. 
S2. The overall difference between treated and untreated patient samples did not reach 
statistical significance (p=0.139, Monte‐Carlo test, 999 permutations, Fig. 3C), thus the 
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gefitinib treatment effect seems to be mostly restricted to dephosphorylation of the 
EGFR. Exclusion of 4 cases from the analysis who did not adhere strictly to the protocol, 
such as extended pre-treatment period (3 cases), or missed drug intake on the day of 
surgery (1 case) did not reveal other significant factors. 
An interaction map of the pathway, indicating the analyzeded proteins, and a 
heatmap of the phosphorylation profiles are shown in Fig. 4. The dendrogram from this 
unsupervised analysis suggests that EGFR signaling was not dominating the activity of 
the pathway. In fact EGFR phosphorylation was least related to pathway activation as 
indicated by principal component analysis (PCA) of all measured phospho-proteins (Fig. 
4C). The closest correlation was with pPDGFR-B (Pearson correlation r=0.5) (Fig. S3, 
shows all pairwise comparisons), however, the amplitude of pPDGFR-B was much lower 
(Fig. S3,4). Information on expression of PTEN, CycD and p-mTOR was obtained by 
immunohistochemistry on the respective TMA, included as label to the heatmap (Fig. 
4B). 
 
Effect of gefitinib on EGFR signaling pathway in an in vitro and in vivo model 
In parallel to the human clinical trial we investigated gefitinib modulation of EGFR 
signaling in an in vitro and in vivo model to facilitate interpretation of the human data. 
The human glioblastoma cell line BS-153, with inherent amplification and 
overexpression of the EGFR and overexpression of the mutant EGFRvIII (Fig 1, 5), was 
subjected to gefitinib treatment in vitro and in vivo. In vitro experiments carried out over 
24 h showed as expected dephosphorylation of the EGFRwt&vIII, and also reduced 
phosphorylation of key signal transductors, such as AKT that is involved in cell survival 
signaling, and p90RSK a regulator of cell growth and differentiation (Fig. 5). Treatment 
of mice with established subcutaneous BS-153 xenografts according to the human 
gefitinib dosing schedule also resulted in efficient dephosphorylation of the 
EGFRwt&vIII. However, in contrast to the in vitro experiments phosphorylation of 
downstream signal transductors were not modulated. Hence, in the in vivo setting the 
results are similar to those obtained from the human glioblastoma samples. Interestingly, 
mTOR and elF4G that are involved in nutrition sensing and regulation of protein 
translation, respectively, were generally less activated in the BS-153 xenograft tissues 
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as compared to the cell lines in vitro. This may indicate differences of metabolism in the 
two model systems. Modulation of mTOR and elF4G phosphorylation was observed in 
vitro upon stimulation with EGF or treatment with gefitinib (Fig 5).  
 
 
DISCUSSION 
Small molecule inhibitors of the EGFR have shown little activity in glioblastoma 
despite the fact that this pathway is affected through amplification of the EGFR gene in 
around 50% of patients. The present phase II trial was aimed at elucidating gefitinib 
mediated modulation of known EGFR downstream signaling. Patients were moved onto 
non-EIAEDs before study entry, to exclude reduced drug exposure through induction of 
CYP3A4. Intra-tumoral gefitinib concentrations reached high levels that were 20-times 
higher than the respective plasma concentrations, when measured within 8 h from the 
last drug intake. Most importantly, gefitinib treatment was associated with efficient 
dephosphorylation of the EGFR. This is in contrast to tumor drug concentrations 
reported for erlotinib or its active metabolite (OSI-420) that were low, and reaching only 
6 to 50% of the respective plasma concentrations 24,25. It may thus not be surprising that 
the authors reported inconsistent EGFR dephosphorylation in the respective tumor 
tissues 24,25.  
Despite the efficient EGFR dephosphorylation by gefitinib, a phospho-screen of 
signal transducers downstream of EGFR did not show a statistically significant 
modulatory effect on the pathway, although a trend for increased phosphorylation of 
ERK1/2 was observed (Table S1). This is counterintuitive, since a decrease if anything 
would have been expected according to the interaction map of the pathway. The overall 
inertness of the pathway signal transductors to EGFR dephosphorylation by gefitinib 
may not surprise given our observation that EGFR phosphorylation was not indicative of 
overall activation of the pathway regardless of the treatment (Fig. 4C). It has been 
proposed that the signaling network, constituted by the ERBB family of receptors of 
which EGFR is a member (ERBB1), and other mitogenic receptors involved in the 
malignant behavior of glioblastoma such as MET, or PDGFR, is very robust, since it 
shares modularity (parts of the pathway), and shows redundancy of regulatory circuits 
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26,27. Interestingly, an in vivo model treating established human tumor xenografts with 
endogenous amplification and overexpression of the EGFRwt & vIII, recapitulated the 
efficient EGFR dephosphorylation by gefitinib in glioblastoma, and reproduced lack of 
downstream signaling modulation. In contrast, treatment of the same cell line in vitro 
modulated phosphorylation of the signal transductors, thus failing to predict in vivo 
behavior. Reasons comprise the fact that in vitro experiments usually model acute 
exposure (here 24 h), while treatment in glioblastoma and in vivo models may allow 
escape through adaptive changes utilizing the redundancy of the regulatory circuits. 
Moreover, respective analysis at resection likely shows a snapshot of a newly 
established steady state. In addition, in vitro systems lack stress signaling induced in 
vivo by metabolic stress, or hypoxia that share some of the downstream signal 
transductors. 
In conclusion, the present study suggests that the EGFR inhibitor gefitinib 
reaches the tumor in high concentrations, efficiently dephosphorylates the target, 
however, this does not suffice to control pathway activity. EGFR-phosphorylation 
independent regulatory circuits seem to dominate the pathway. In order to find 
therapeutic opportunities, the fragilities of the network need to be enquired that may help 
to design promising combination therapies for patients with respective molecular 
characteristics 26,28. 
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Figure Legends 
Figure 1. EGFR amplification and expression in glioblastoma. EGFR copy number 
corresponding to the maximum value determined by FISH on the TMA or qPCR on 
whole tissue sections are represented by black lines (left scale). Expression of EGFRwt 
(filled triangle, red) and EGFRvIII (open triangle, red) was determined by qRT-PCR, the 
scale on the right hand side applies. The samples called 'xeno0' and 'xeno1' indicate the 
averaged values for the untreated and treated BS-153 xenografts in mice, respectively. 
EGFRvIII expression was detected in two glioblastoma at modest levels not exceeding 
expression of EGFRwt. BS-153 xenografts displayed high expression of EGFRvIII 
greater than EGFRwt.  
 
Figure 2. Gefitinib concentrations in the tumor tissue and plasma. 
Gefitinib concentrations were measured in the tumor tissue and plasma obtained after a 
median time laps of 5 h and 5 h 30 min after the last gefitinib intake, respectively. The 
median gefitinib concentration in the tumor tissue was 20-times higher than in the 
plasma (4,100 ng/g, range 16 to 26,000 ng/g; 181 ng/ml,range 4 to 483 ng/ml; 
p<0.0001). One patient did not take the drug on the day of surgery (>24 h), reflected in 
very low drug concentrations in the tumor and the plasma, respectively. 
 
Figure 3. Effect of gefitinib on EGFR pathway signaling transductors. Fourteen signaling 
transductors of the EGFR pathway were determinded by Bio-Plex technology and 
normalized to tot-ERK1/2. The log2-intensity of the p-EGFR (A) and p-ERK1/2 (B) 
measured in the tumor tissues from patients under gefitinib treatment (T1, red) or a 
control cohort (T0, blue) are represented in box plots stratified by the EGFR 
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amplification status (A1, amplified; A0, not amplified). A significant decrease was found 
for pEGFR (p=0.006, Kruskal & Wallis test), and a trend for higher pERK1/2 (p=0.1). 
Overall differences over the 14 measured phospho-proteins between tumors under 
gefitinib treatment and controls are not significant (C). Box plots for the other 12 
phospho-proteins are available in Fig. S2. 
 
Figure 4. Modulation of the EGFR signaling pathway. (A) The EGFR pathway 
interaction map is adapted from Bertotti et al. 29 and indicates the phospho-proteins 
measured by Bio-Plex analysis in pink, and proteins determined by 
immunohistochemistry on the TMA or by Western in yellow. (B) The heatmap clusters 
the samples and phospho-proteins by similarity. Tumors with EGFR amplification are 
marked in green (A1; no amplification A0, light green). Tumors under gefitinib treatment 
are indicated in red (T1), and blue for the controls (T0). For one patient with an amplified 
EGFR a sample at second relapse was obtained and showed high p-EGFR (ZH-06b) in 
contrast to the tumor under gefitinib treatment (ZH-06a). Sample *2510 is the recurrent 
glioblastoma of *2505. A heatmap without scaling and centering is available as Fig. S4 
that visualizes the differences in amplitude of the different phospho-proteins. The 
pathway constituents PTEN, CycD, and mTOR were evaluated semi-quantitatively by 
immunhistochemistry and have been added as labels (blue, no expression; grades of 
pink, increasing expression 1-3; white, no information; for mTOR, 0/vs, tumor negative 
vessels positive, dark blue). The dendrogram of the phospho-proteins indicates that p-
EGFR is very distant to the other pathway signaling transductors. (C) The Principal 
component analysis (PCA) of the phospho-proteins shows the first vectorial plan based 
on the correlation matrix. The first axis of the PCA represented 62% of the variance 
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(total inertia) of the table and organized the phospho-proteins in function of their total 
intensity. All phospho-proteins were turned in the same sense, with the exception of p-
EGFR and to a lesser extent p-PDGFR-B. The second axis was mainly built by the 
variable p-EGFR and it explained 9.2% of the variance of all phospho-proteins. On the 
first vectorial plan of the PCA, we observe that the expression of p-EGFR is not 
correlated with the other phospho-proteins, except for p-PDGFR-B (r=0.527). Pairwise 
correlations of all phospho-proteins are displayed in a matrix of scatter plots in Fig. S3. 
 
Figure 5. Modulation of the EGFR pathway by gefitinib in vitro and in vivo. The human 
glioblastoma cell line BS-153 was treated in vitro with EGF or 1 and 5 M gefitinib for 24 
h. Of note, 5 M gefitinib already had some toxic effects on the cells. Nude mice with 
established subcutaneous BS-153 xenografts (diameter ca. 1 cm) were treated 5 days 
with gefitinib according to the human schedule. The activation status of the EGFR 
pathway was measured in all protein extracts by Bio-Plex technology in parallel with the 
human glioblastoma tissues (Fig. 4). (A) A heatmap for the phospho-proteins normalized 
by tot-ERK1/2 is shown (without scaling and centering). In the xenografts gefitinib 
treatment reduced pEGFR, while in the in vitro experiment several signaling 
transductors were modulated including p-AKT. Three of the phospho-proteins are also 
shown by Western analysis (B), confirming the results obtained by Bio-Plex analysis. In 
addition, p-mTOR and p-elF4G were measured, indicating that these signal transductors 
of metabolism sensing and protein translation were generally lower in the xenografts as 
opposed to the in vitro model. 
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Table 1. Baseline Patient Characteristics 
 
 Gefitinib Group, n=22 Control Group, n= 12 
Characteristic Number of Patients 
(%) 
Number of Patients 
(%) 
Median age, years (range) 52 (24-69) 62 (31-70) 
Gender 
 Male 
 Female 
 
ECOG performance status 
0 or 1 
2 
Unknown 
 
Treatments prior to re-resection 
 S, RT, TMZ 
 S, RT+TMZ, TMZ 
 S, RT 
 Other/unknown  
 
14 (64) 
8 (36) 
 
 
18 (82) 
3 (14) 
1 (5) 
 
 
10 
11 
0 
1 
 
7 (58) 
5 (42) 
 
NA 
 
 
 
 
 
5 
2 
4 
2 
EGFR amplification status* 
 amplified 
 non-amplified 
 
7 (32) 
15 (68) 
 
7 (58) 
5 (42) 
Frozen Tissue for pathway analysis 
 Adequate tissue available  
 Predominantly necrotic, inadequate 
quality 
 Tumor tissue not available 
 
14 (64) 
5 (23) 
 
3 (14) 
 
10 (83) 
2 (17) 
 
- 
*for 3 samples the EGFR status was inferred from a previous resection 
Abbreviation: ECOG, Eastern Cooperative Oncology Group, WHO, World Health 
Organization; NA, not available; S, Surgery; RT Radiation Therapy; TMZ, Temozolomide; 
RT+TMZ, combined radio-chemotherapy with TMZ 
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Figure S1. Study outline. Patients selected for re-operation of a recurrent 
glioblastoma were enrolled in this phase II trial and were treated at least 5 days with 
500 mg gefitinib prior to surgery, followed by post-operative daily use, continuously 
until tumor progression or occurrence of intolerable side effects. Resected tumor 
tissue was collected for translational research. Control tissues were obtained from re-
resection of glioblastoma of patients treated outside clinical trials.  
 
Figure S2. Effect of gefitinib on EGFR pathway signaling transductors. Fourteen 
signaling transductors of the EGFR pathway were measured by bioplex technology in 
tumor tissues under gefitinib treatment (T1, red) or controls (T0, blue). The log2-
intensities of the phopsho-proteins, normalized by tot-Erk-1/2, are represented by box 
plots, stratified by the EGFR amplification status (A1, amplified; A0, not amplified).  
 
Figure S3. Pairwise comparisons of phospho-proteins. A matrix of scatterplots of the 
bioplex values (n=26 tumor samples, table normalized by t-Erk1/2) is shown. The 
lower triangle contains the cloud point representation between each variable (the 
loess smoothed curve is depicted in red). The upper triangle contains the values of 
Pearson correlation coefficients. The diagonal contains the histogram of each 
phosphor-protein. 
 
Figure S4. Pattern of EGFR pathway activation in glioblastoma. The heatmap 
clusters the samples and phospho-proteins by similarity based on ward classification 
and euclidean distance. The dataset is normalized by total-Erk1/2, but neither scaled 
1 
 
2 
 
nor centered. Tumors with EGFR amplification are marked in green. Tumors under 
gefitinib treatment are indicated in red (T1), and blue for the controls (T0). This 
representation visualizes the fact that the amplitude varies a lot among the different 
phospho-proteins, e.g. between pEGFR and p-PDGFR-B. All labels are described in 
Fig. 4B. 
 
 
 
Table S1   Association of EGFR pathway signal transduction with gefitinib treatment   
              
 Association with gefitinib treatment Associaton with gefitinib treatment  
     stratified for EGFR status  
P-proteins statistic. wilcox p.value. wilcox p.adj.wilcox statistic.kruskal* p.value.kruskal p.adj.kruskal 
p-p38MAPK 88 0.860 1.000 0.233 0.972 1.000 
p-p90RSK 60 0.231 1.000 3.468 0.325 1.000 
p-Akt 72 0.560 1.000 1.039 0.792 1.000 
p-c-Jun 70 0.494 1.000 1.637 0.651 1.000 
p-EGFR 122 0.053 0.632 12.358 0.006 0.075 
p-Erk1&2 49 0.076 0.908 6.157 0.104 1.000 
p-GSK 3a/b 63 0.297 1.000 4.464 0.216 1.000 
p-MEK1 62 0.274 1.000 3.516 0.319 1.000 
p-NFkB p65 73 0.595 1.000 2.085 0.555 1.000 
p-P70 S6-K 57 0.176 1.000 4.035 0.258 1.000 
p-S6-RP 73 0.595 1.000 3.614 0.306 1.000 
p-Stat3 71 0.527 1.000 2.870 0.412 1.000 
              
**p-Src(Tyr416) 70 0.494  - 4.425 0.219  - 
**p-PDGFR_B 78 0.781  - 2.635 0.451  - 
* degree of freedom = 3      
**not considered as downstream EGFR pathway constituent, not included for Bonferroni correction  
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